Navigation Links
Sosei Announces Start of AD 923 Phase III Studies in Europe

TOKYO, Japan, February 12 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that it has commenced Phase III studies for its fentanyl sublingual spray (AD 923), an opioid analgesic for the treatment of cancer breakthrough pain.

The trial is a multi-centre, randomised, double-blind, double-dummy, crossover study to evaluate the safety and efficacy of AD 923 against an active comparator (morphine sulphate immediate release (MSIR)) for the treatment of breakthrough pain in patients with malignancies. The primary endpoint is the well established summary of pain intensity difference (SPID) measure over the first 30 minutes from initial dosing.

Overall, the European Phase III programme will involve some 300 patients in two studies, involving an active comparator, across 10 European countries. These will then be followed by a single combined open label study to assess the long term effectiveness, safety and tolerability of AD 923.

In June 2006, Sosei entered into an agreement with Mundipharma International Corporation Limited for the development and commercialisation of AD 923 in Europe and other international markets, excluding North America and Japan. Sosei is currently evaluating its commercialisation options for the un-partnered territories.

Mr Shinichi Tamura, President & CEO of Sosei, said: "I am delighted that we are able to announce the start of Phase III studies. AD 923 has been optimised to meet the well recognised need for a safe and effective method of delivering fentanyl for the rapid relief of breakthrough pain in malignant and also non-malignant conditions."

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit

About Cancer Breakthrough Pain

Cancer breakthrough pain is characterised by temporary exacerbations of moderate to severe pain in cancer patients that "breakthrough" their around-the-clock opioid treatments. Each episode may be spontaneous or incidental to an activity. The recent European Pain in Cancer Survey (EPIC) results reveal that cancer related pain is widespread in Europe, with one in two (56%) cancer patients enduring moderate to severe pain (n=5,084). The second, detailed phase of the survey reveals that cancer breakthrough pain or inadequate pain relief is a common problem for many patients - 63% of patients in Europe prescribed analgesia, report that they are affected by breakthrough pain (n=441). It also highlights that breakthrough pain can be a frequent occurrence - 26% experiencing it at least once a day (n=279). For further information please visit

Most current treatments for cancer breakthrough pain are considered sub-optimal. The market seeks products which have a rapid onset of action and are easy to use. The current worldwide market for cancer breakthrough pain drug treatment is estimated to be worth $1.5bn and represents a growing market opportunity.

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
2. Sosei Announces Update on Phase I Trials for SD118
3. Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
(Date:10/13/2015)... ... ... Sir Grout of Greater Boston donated an expansive, seven room tile and ... (RMHC®). This donation was made in an effort to give back to the local ... “We believe strongly in the Ronald McDonald House Charities, and they are truly a ...
(Date:10/13/2015)... , ... October 13, 2015 , ... "My friend's son ... fists into his infected cheeks," said an inventor from Platteville, Colo. "I came up ... problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or scratching ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... pain management services, today announced its partnership with WPC Healthcare , a ... disparate systems and organizes the data into an aggregated data repository necessary to ...
(Date:10/13/2015)... ... , ... According to an article published October 5th by the ... lose weight with a bariatric procedure are much less likely to develop endometrial cancer, ... anywhere from 40 to 50 percent of all endometrial cancer cases are caused by ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take ... and NAVUG Summit are independent user conferences designed and led by users to ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015   Vigilant Biosciences, Inc. ("Vigilant"), a ... the early detection and intervention of cancer, announced today ... CEO, Matthew H.J. Kim , the Weaver H. ... entrepreneur who has made extraordinary contributions to the growth ... in the leadership of a company or institution. ...
(Date:10/13/2015)... Oct. 13, 2015 WuXi PharmaTech (Cayman) ... technology platform company serving the pharmaceutical, biotechnology, and ... launched a mobile version of OncoWuXi, the first ... access oncology models and data on the go.  ... at any time to identify relevant tumor models ...
(Date:10/13/2015)... , Oct. 13, 2015   Happy ... direct-to-consumer laboratory home testing kit for breast ... technologies provide an unparalleled, detailed assessment of ... milk—fats, proteins, carbs and key vitamins—all charted ... for personal health tracking.  In addition, Happy Vitals ...
Breaking Medicine Technology: